Leptin appears to exert a dual action in experimental NAFLD models; it protects against liver steatosis, at least in the early stages of the disease, but it also acts as an inflammatory and fibrogenic mediator when the disease persists or continues (133). The gene discussed is LEP; the disease is metabolic dysfunction-associated steatotic liver disease.